Psychedelics Investing 101 | Signals by AlphaSense Podcast

In this episode of Psychedelic Investment Insights, host Nick Mazing from AlphaSense sits down with Dan Ahrens, the portfolio manager at AdvisorShares Psychedelics ETF (NYSE: PSIL). Together, they delve into the rapidly evolving world of psychedelic investments and the key differences between investing in the psychedelic and cannabis sectors. Dan highlights the importance of understanding the psychedelic market as a biotech-driven industry and discusses its unique challenges and opportunities.
Throughout the conversation, Dan outlines the factors investors should consider when examining psychedelic companies, such as their intellectual property and FDA pipeline. He also shares valuable insights about the major players in the sector, including Compass Pathways and Cybin, and how their groundbreaking treatments have the potential to revolutionize mental health care.
Finally, the discussion turns to the advantages of investing in a psychedelics-focused ETF, like AdvisorShares' PSIL, which offers investors transparency and exposure to a curated selection of innovative companies within the industry. This episode is a must-listen for anyone interested in the growing field of psychedelic investments and the future of mental health treatments.
Listen on:
Apple: podcasts.apple.com/us/podcast...
Spotify: open.spotify.com/episode/3WbA...
Google: podcasts.google.com/feed/aHR0...[…]NTE5Mw?sa=X&ved=0CAUQkfYCahcKEwjA0I39-43_AhUAAAAAHQAAAAAQCg
---
AlphaSense is a market intelligence and search platform used by the world’s leading companies and financial institutions.
→ Learn more about AlphaSense:
www.alpha-sense.com
→ Learn more about Stream by AlphaSense:
www.streamrg.com
→ Engage with AlphaSense:
Twitter: / alphasenseinc
LinkedIn: / alph. .
Facebook: / alphasenseinc
Instagram: / alphasenseinc
Podcast: open.spotify.com/show/2Fpmsp1...
Blog: www.alpha-sense.com/blog